Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

February 29, 2028

Study Completion Date

August 31, 2028

Conditions
HIV-1-infection
Interventions
DRUG

Lenacapavir

Tablets administered orally without regard to food

DRUG

BIC/LEN FDC

Tablets administered orally without regard to food

Trial Locations (19)

1862

RECRUITING

Perinatal HIV Research Unit, Johannesburg

2038

RECRUITING

Wits RHI Shandukani Research Centre CRS, Johannesburg

2112

RECRUITING

Nkanyezi VIDA Research Unit, Johannesburg

3629

RECRUITING

Durban International Clinical Research Site, Enhancing Care Foundation, Durban

4449

RECRUITING

Clinical Research Institute of South Africa (CRISA), KwaDukuza

7505

ACTIVE_NOT_RECRUITING

FAMCRU Ukwanda School for Rural Health, Cape Town

7646

RECRUITING

Be Part Yoluntu, Cape Town

20010

RECRUITING

Children's National Hospital, Washington D.C.

20157

RECRUITING

ASST FBF Sacco Ospedale Sacco, Milan

28007

RECRUITING

Hospital General Universitario Gregorio Marano, Madrid

28041

RECRUITING

Hospital Universitario 12 De Octubre, Madrid

28046

RECRUITING

Hospital Universitario La Paz, Madrid

30308

RECRUITING

Grady Ponce de Leon Center, Atlanta

33612

RECRUITING

University of South Florida, Tampa

60614

RECRUITING

Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago

C1141ACG,

RECRUITING

Helios Salud S.A, Buenos Aires

00165

RECRUITING

IRCCS Ospedale Pediatrico Bambino Gesu, UOS Infezioni Complesse e Perinatali, Roma

0087

RECRUITING

The Aurum Institute: Pretoria Clinical Research Centre, Pretoria

0152

ACTIVE_NOT_RECRUITING

Setshaba Research Centre, Soshanguve

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT06532656 - Study of Bictegravir/Lenacapavir in Children and Adolescents With HIV-1 | Biotech Hunter | Biotech Hunter